Prescriptions for Wegovy rose sixfold between December 2022 and June 2023 while those for Ozempic jumped 65%, with general and family practice providers writing the majority of prescriptions.
Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?
Increased fracture risk seen in short-term studies may have been due to hypovolemia or osmotic diuresis, resulting in falls, rather than an effect on bone.
Taiwan: A recent study in Scientific Reports has revealed that co-administration of metformin and sodium-glucose co-transporter 2 (SGLT2) inhibitors delays the progression of diabetic retinopathy (DR).
Four experts explain nuances of the multidrug strategy and why it should be easy to implement. Given its slow uptake in practice, what forces are conspiring against it?